Sponsors (7)
The bill would speed and clarify generic approvals—helping patients access lower-cost drugs and reducing developer uncertainty—at the cost of greater public disclosure of formulation details, added FDA workload, and reduced post-filing regulatory flexibility that could limit rapid safety responses.
Patients with chronic conditions gain faster access to lower-cost generic medicines because FDA sameness determinations would be final after ANDA filing, reducing the chance of post-filing reversals that can delay approvals.
Generic manufacturers and applicants (including small businesses) get clearer, binding determinations about whether a proposed product is qualitatively and quantitatively the same as the listed drug, reducing regulatory uncertainty and helping speed development and filing decisions.
Applicants get greater transparency because FDA must identify specific inactive-ingredient differences and quantify deviations, enabling developers and regulators to address formulation issues more efficiently.
Patients and health systems could face increased safety or quality risk if FDA loses flexibility to change sameness determinations after ANDA filing, limiting the agency's ability to act on newly discovered problems except under narrow exceptions.
Requiring disclosure of specific inactive-ingredient differences and quantitative deviations may reveal commercially sensitive formulation details, creating competitive harm or intellectual-property risk for brand and generic manufacturers.
FDA would face increased administrative burden and resource needs to provide determinations, notifications, draft guidance, and handle controlled correspondence within mandated timelines, potentially diverting agency resources from other oversight activities.
Based on analysis of 2 sections of legislative text.
Introduced April 3, 2025 by Margaret Wood Hassan · Last progress April 3, 2025
Requires the FDA to tell current or prospective generic drug applicants (ANDA filers) whether a proposed generic product is qualitatively and quantitatively the same as the listed (brand) drug, and if not, identify which inactive ingredients differ and how much any quantitative deviations are. FDA must provide this information on request (including via controlled correspondence), may provide it proactively during review, and must issue guidance within a specified timetable describing how sameness is determined. Once FDA finds a proposed product is the same and an ANDA is filed, that determination generally cannot be changed except in narrow safety/error situations.